Lantus, the new long-acting insulin

Patients are asking about Lantus, the new long-acting insulin.

Health Canada has approved Lantus (insulin glargine)...but Aventis is delaying the launch until they have adequate supplies.

Insulin glargine is a synthetic insulin that differs from human insulin by 3 amino acids. It forms a microprecipitate in subcutaneous tissue...which delays and prolongs its absorption.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote